Autologous Hematopoietic Stem Cell Transplantation and Mobilization in Multiple Myeloma: Current Debate and Developments
This activity contains:
- CME-Certified Video Viewpoints
Release date: 10/2/2017
Estimated time for completion: 30 minutes each
The goal of this activity is to provide clinicians with the latest evidence-based information regarding autologous hematopoietic stem cell transplantation and mobilization in multiple myeloma, to be able to translate current and emerging evidence into real-world clinical practice.
In the age of immunomodulatory agents, proteasome inhibitors, and other novel agents for the treatment of multiple myeloma (MM), the role of autologous hematopoietic stem cell transplantation (ASCT) has become an area of debate. Whereas most oncologists recognize a role for ASCT in the up-front treatment of MM, this view is not universally shared, particularly when it comes to treating younger patients with MM (<65 years old). Comorbidities were cited in a recent survey of perceptions and practices of oncologists and transplant specialists as the most frequent reason younger patients with a clinical indication for ASCT would not be referred to a transplant specialist. Although advanced age and comorbidities can limit eligibility for ASCT, these concerns are not absolute contraindications for ASCT. The use of plerixafor and captisol-enabled melphalan are advancing the limits of what can be achieved by ASCT in patients with MM.
This activity is a web-based, on-demand activity, featuring an expert panel discussion. This activity is designed as a forum for the debate and evaluation of the most recent clinical data, and to provide evidence-based updates and expert insights on the discussion points to translate current and emerging evidence into real-world clinical practice.
This activity is intended for hematologists, transplant specialists, and other clinicians.
At the conclusion of this activity, participants should be better able to:
- Review outcome data for patients with multiple myeloma who receive versus those who do not receive autologous hematopoietic stem cell transplantation
- Compare data between patients with multiple myeloma who receive early versus delayed autologous hematopoietic stem cell transplantation
- Discuss guidelines about the recommended timing and eligibility for autologous hematopoietic stem cell transplantation
- Consider data regarding the impact of comorbidities on the utility of autologous hematopoietic stem cell transplantation for patients with multiple myeloma
- Choose mobilization strategy based on patient-specific needs and drug-specific characteristics
- Compare stem cell mobilization and transplantation efficacy with standard melphalan to captisol-enabled melphalan and other drugs used for induction therapy in patients with multiple myeloma
- Compare the safety profiles of standard melphalan to captisol-enabled melphalan and other drugs used for induction therapy in patients with multiple myeloma
Parameswaran Hari, MD
Nina Shah, MD
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflict of Interest
AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
Parameswaran Hari, MD
Parameswaran Hari, MD, reported a financial interest/relationship or affiliation in the form of Advisory board/consulting, Celgene Corporation, Sanofi, Bristol-Myers Squibb Company, Spectrum Pharmaceuticals, Inc., and Takeda Pharmaceutical Company; Kite Pharmaceuticals; Research grant, Takeda Pharmaceutical Company.
|Nina Shah, MD||Nina Shah, MD, reported a financial interest/relationship or affiliation in the form of Advisory board/consulting, Takeda Oncology, Celgene Corporation, Indapta Corporation; Received income in any amount from, Celgene Corporation.|
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
The following AXIS planners and managers, Linda Gracie-King, MS and Jocelyn Timko, BS, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.
This activity is provided by an educational grant from Sanofi Genzyme.
There is no fee for this educational activity.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ACPE
- 1.00 ANCC
- 1.00 Attendance